Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Publication | Open Access

DOI Full Paper Access

154

Citations

References

2023

Year

Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Jake Shortt, David Valcárcel, Anna Jonášová, Sophie Dimicoli‐Salazar, Ing Soo Tiong,

The Lancet

Hematological MalignancyThrombosisInterim AnalysisBone Marrow FailurePhase 3Blood TransfusionTransfusion MedicineHematologyClinical TrialsPharmacotherapyLower-risk Myelodysplastic SyndromesMedicineAplastic AnemiaEmergency MedicineHealth Sciences